Viking Therapeutics, Inc. Cash and Restricted Cash
Viking Therapeutics, Inc. (VKTX) had Cash and Restricted Cash of $36.63 million as of 2022-12-31, per its 10-K filed 2023-02-10.
Discontinued › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2023-02-10
- 2022-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $36.63M.
- 2022-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $12.45M.
- 2021-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $26.37M.
- 2021-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $11.26M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2022-12-31 | $36.63M 10-K · filed 2023-02-10 |
| 2022-03-31 | $12.45M 10-Q · filed 2022-04-27 |
| 2021-12-31 | $26.37M 10-K · filed 2023-02-10 |
| 2021-09-30 | $11.26M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $8.83M 10-Q · filed 2021-07-28 |
| 2021-03-31 | $16.80M 10-Q · filed 2022-04-27 |
| 2020-12-31 | $29.12M 10-K · filed 2023-02-10 |
| 2020-09-30 | $3.87M 10-Q · filed 2021-11-03 |
| 2020-06-30 | $18.79M 10-Q · filed 2021-07-28 |
| 2020-03-31 | $15.26M 10-Q · filed 2021-04-28 |
| 2019-12-31 | $8.38M 10-K · filed 2022-02-09 |
| 2019-09-30 | $30.95M 10-Q · filed 2020-10-28 |
| 2019-06-30 | $19.12M 10-Q · filed 2020-07-29 |
| 2019-03-31 | $14.34M 10-Q · filed 2020-04-30 |
| 2018-12-31 | $24.78M 10-K · filed 2021-02-17 |
| 2018-09-30 | $169.51M 10-Q · filed 2019-11-05 |
| 2017-12-31 | $8.99M 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |